OncoMatch/Clinical Trials/NCT06922591
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Is NCT06922591 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for pdac.
Treatment: TNG462 · RMC-9805 · RMC-6236 · mFOLFIRINOX · gemcitabine/nab-paclitaxel — TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Pancreatic Cancer
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: MTAP loss of protein
Has a tumor with loss of MTAP protein
Required: MTAP bi-allelic deletion
bi-allelic deletion of the MTAP gene
Required: KRAS mutation
Arms A and B only: Has a tumor with a RAS mutation
Required: NRAS mutation
Arms A and B only: Has a tumor with a RAS mutation
Required: HRAS mutation
Arms A and B only: Has a tumor with a RAS mutation
Disease stage
Required: Stage IV, III
metastatic PDAC or locally advanced, recurrent or metastatic NSCLC
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy
Has received prior standard therapy
Cannot have received: RAS-targeted therapy
Exception: Arms A and B only
Arms A and B only: Must not have received prior RAS-targeted therapy
Cannot have received: PRMT5 inhibitor
Has received prior treatment with a PRMT5 inhibitor
Cannot have received: MAT2A inhibitor
Has received prior treatment with a MAT2A inhibitor
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Scottsdale · Scottsdale, Arizona
- Sarah Cannon Research Institute Denver · Denver, Colorado
- Mayo Clinic Jacksonville · Jacksonville, Florida
- University of Indiana · Indianapolis, Indiana
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06922591 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior RAS-targeted therapy, PRMT5 inhibitor, MAT2A inhibitor disqualifies patients from enrollment.
Does this trial require MTAP?
Yes, MTAP loss of protein is a required biomarker for enrollment.
Does this trial require MTAP?
Yes, MTAP bi-allelic deletion is a required biomarker for enrollment.
Does this trial require KRAS?
Yes, KRAS mutation is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV or III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify